HER2-Positive Breast Cancer

Gregory Vidal, MD, PhD, on Treating Patients with HER2+ Breast Cancer During COVID-19

October 16, 2020

The breast cancer expert discussed the changes he has made in treating this patient population as a result of the COVID-19 pandemic.

Addition of Tucatinib to Trastuzumab, Capecitabine Improves Survival in HER2+ mBC

September 21, 2020

The addition of tucatinib to trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer with and without brain metastases resulted in statistically significant and clinically meaningful improvements in progression-free and overall survival.

First Patient Dosed in Phase 1 Study of NK Cell Therapy, ACE1702

August 19, 2020

The study is designed to evaluate the safety and tolerability, pharmacodynamics, and preliminary efficacy of ACE1702 in patients with advanced or metastatic HER2-expressing solid tumors.